STAT3 and plasma cell myeloma: We next used three established OvCa cell lines to examine formally the potential for synergistic interactions between JMS-053 and two drugs that are clinically used to treat OvCa, paclitaxel and olaparib, as well as a previously described inhibitor of the STAT3 pathway 864,669 [20] and a SHP2 inhibitor SHP009 [4], because of the reported role of STAT3 and SHP2 phosphatase in a feedforward loop in multiple myeloma [31].